May be a person thinking about the rule презентация

This borders on arrogance.
If you wait to be 100% confident it probably means that someone else may have already capitalized
on your idea because you spent too much time in the quest for perfection.
And if you are 100% right the first time, it is pure chance, not genius.

FIGURE 1 (page 16): An illustration that embodies the rule – may be a person thinking about the rule?

The 80-80 Rule
"Being 80% confident that you will only be 80% right the first time should feel normal”

the unicorn and the body representing biopharma industry, flapping its wings to signify take off and growth

biopharma manufacturers emerged

from early days of the industry

showing the kind of information included (something better than below)

off in mid-90s.

1985 - 2015

jet propulsion behind, and blockbusters in the jet stream

Image of unicorn

down, wings beginning to flap, but showing a lower trajectory of flight + graph below showing average revenues per product

Source: https://www.forbes.com/sites/peterubel/2016/07/29/is-the-golden-era-of-pharmaceutical-profits-over/#494789c17207

stakeholders scrambling

Business Model

Monetize Core Capabilities

CORE

Develop “Smart” Products

BUSINESS MODEL

SAME

DIFFERENT

INNOVATION

PRODUCT FOCUS

PRODUCT+ SERVICE
FOCUS

Reverse the Revenue Equation

Figure 12 (page 72)

The Y-axis displays opportunities across the three forms of innovation described in the prior section. The X-axis displays the evolution of a company’s overall business model over time which encompasses where and how it generates revenue and the way it engages with the market through its customer engagement or commercial model.

p x V

Superimposed on -

Current: Image of the world with US, EU and Japan shown as big compared to Asia, LatAm

Future: A normal map of the world

products released between 2005 and 2009 barely broke even:

Source: https://www.forbes.com/sites/peterubel/2016/07/29/is-the-golden-era-of-pharmaceutical-profits-over/#494789c17207

smart pill in stomach, throwing out data such as cold, thirsty, hungry, sleepy – being received by airline stewards who are bringing water, blankets, dimming lights, bring food in response….

Patient Involvement: Taking medication. Manufacturer Involvement: Pharmacovigilance through spontaneous reporting. Examples: All self-administered prescription products.

Level 1: Passive Medication Adherence
Smart Capability: Passive Medication Reminders. Provider involvement: Prescribing & administering. Patient Involvement: Taking medication. Manufacturer Involvement: Pharmacovigilance, adherence messaging and monitoring at population level. Examples: Smart Pill Bottles & Dispensers
 

Level 2: Active Medication Adherence
Smart Capability: Ingested Medication Reminders that alert patients when medicine concentration falls below a threshold within the body. Provider involvement: Prescribing & administering. Patient Involvement: Taking medication. Manufacturer Involvement: Pharmacovigilance. Examples: Otsuka & Proteus Technologies combination product (Abilify + smart chip)
 

Level 3: Assisted Dosing
Smart Capability: Ingested Medication alerts patients and providers when medicine concentration falls below a threshold within the body, side effects and clinical efficacy and effectiveness. Provider involvement: Prescribing, administering., monitoring and adjusting. Patient Involvement: Taking medication and active engagement with provider. Manufacturer Involvement: Enable Patient Provider Dialog. Active Recommendations. Pharmacovigilance. Examples: None

Level 4: Smart Dosing
Smart Capability: Controlled release of ingested medication concentration based on real-time monitoring of side effects, clinical efficacy and effectiveness. Provider involvement: Prescribing, administering, monitoring and adjusting. Patient Involvement: Taking medication. Manufacturer Involvement: Enable Patient Provider Dialog. Active Recommendations. Pharmacovigilance. Examples: None 

Level 5: Healthy Time
Smart Capability: Guarantee of healthy time through active , remote management.. Provider involvement: Part of manufacturer service. Manufacturer Involvement: Enable Patient Provider Dialog. Active Recommendations. Pharmacovigilance. Patient Involvement: Taking medication. Examples: None

RKJH 2017 Standards to define levels of “smart” features in therapeutics that can enable manufacturers, regulators, payers, providers and patients create approval, administration and reimbursement policy frameworks and drive evolution of “smart therapeutics.” – © Ruchin Kansal & Jeff Huth. 2017

Smart Therapeutics

Driverless Cars

Figure 16 (page 80)

Equation

Strengthen the Core Business Model

Monetize Core Capabilities

CORE

Develop “Smart” Products

BUSINESS MODEL

SAME

DIFFERENT

INNOVATION

PRODUCT FOCUS

PRODUCT+ SERVICE
FOCUS

NEW INDUSTRY

Figure 17 (page 88)

warp speed (star wars kind of imagery), with smart therapeutics in its jet stream….

figure 1 and the 4 principles for igniting growth

Setting up for success
Finding White Spaces
Developing New Ventures
Becoming Adept at Partnering

leader in the center and the pack moving forward together….

generators
Technical experts
Project managers
Innovation ambassadors
Internal sponsors

“outside in first, inside out next” pointing towards new white space opportunities

green faces

I like the red face image style

hybrid existence. In the middle, insert image of a body which is physical on the left, virtual/digital on the right

ecosystem. comprising patient at the center, and insurance, provider and pharmacy around it. Show biopharma standing outside as a supplier of pills to this ecoosystem.

Current/Future: Show patient, pharma, insurer, pbm, pharmacy, large tech (google/apple), start ups, employers, hospitals, doctors, digital clinics, all part of an integrated healthcare ecosystem, where traditional boundaries of past/current model disappear.